Search
for

    GlossaryShort Anagen Syndrome

    hair growth phase is unusually short, preventing long hair

    Short Anagen Syndrome (SAS) is a condition where the hair growth phase (anagen phase) is unusually short, leading to hair that doesn't grow long and often appears thin or sparse. This results in hair that frequently sheds and doesn't reach its full length potential, making it difficult for individuals to grow long hair.

    Related Terms

    Learn

    4 / 4 results

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

      learn PP405

      mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

      learn Tofacitinib

      a JAK inhibitor for alopecia areata and other autoimmune conditions

    Research

    5 / 1000+ results
      Short Anagen Syndrome

      research Short Anagen Syndrome

      37 citations , July 2005 in “Journal of The American Academy of Dermatology”
      Short anagen syndrome involves a hair growth phase lasting 1.5 years.

      research Short Anagen Syndrome

      28 citations , June 2010 in “Pediatric dermatology”
      Short anagen syndrome causes short hair that may grow longer after puberty.
      Short Anagen Hair Syndrome

      research Short Anagen Hair Syndrome

      11 citations , January 2013 in “International Journal of Trichology”
      Short Anagen Syndrome causes persistently short hair and increased shedding, usually improving after puberty.

    Community Join

    5 / 1000+ results

      community My Theory Of Androgenic Alopecia

      in Research/Science  17 upvotes 1 week ago
      Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

      community What ever happened to pyrilutamide?

      in Technology  48 upvotes 2 years ago
      Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.